Rogaratinib is a Small Molecule owned by Bayer, and is involved in 9 clinical trials, of which 6 were completed, and 3 are ongoing.

Rogaratinib is a pan FGFR1-3 kinase inhibitor with antiangiogenic and antineoplastic activities. The drug candidate selectively binds to and inhibits the activities of FGFRs, which result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.

The revenue for Rogaratinib is expected to reach a total of $396m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rogaratinib NPV Report.

Rogaratinib is originated and owned by Bayer.

Rogaratinib Overview

Rogaratinib (BAY-1163877) is under development for the treatment of non-muscle invasive bladder cancer, metastatic breast cancer, refractory, locally advanced or metastatic solid tumors including squamous non-small cell lung cancer, metastatic urothelial carcinoma including urinary bladder, renal pelvis, ureters, urethra carcinomas, lung adenocarcinoma, squamous cell carcinoma of the head and neck, hepatocellular carcinoma, adenoid cystic carcinoma, gastrointestinal stromal tumor and sarcoma. The drug candidate is administered orally. It acts by targeting fibroblast growth factor receptors (FGFR).

Bayer Overview

Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

The company reported revenues of (Euro) EUR44,081 million for the fiscal year ended December 2021 (FY2021), an increase of 6.5% over FY2020. The operating profit of the company was EUR3,353 million in FY2021, compared to an operating loss of EUR16,169 million in FY2020. The net profit of the company was EUR1,000 million in FY2021, compared to a net loss of EUR10,495 million in FY2020. The company reported revenues of EUR11,281 million for the third quarter ended September 2022, a decrease of 12% over the previous quarter.

Quick View – Rogaratinib

Report Segments
  • Innovator
Drug Name
  • Rogaratinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.